Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argonde C van Harten

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's DiseaseArgonde C van Harten, Joyce Mulders, Philip Scheltens, et al.
Neurobiology of Aging|June 3, 2017
CSF ApoE predicts clinical progression in nondemented APOEε4 carriersArgonde C van Harten, Wesley Jongbloed, Charlotte E Teunissen, et al.
Stroke|July 16, 2015
White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive DeclineMarije R Benedictus, Argonde C van Harten, Annebet E Leeuwis, et al.
Clinical Chemistry and Laboratory Medicine|February 24, 2011
Tau and p-tau as CSF biomarkers in dementia: a meta-analysisArgonde C van Harten, Maartje I Kester, Pieter-Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 13, 2012
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaintsArgonde C van Harten, Pieter Jelle Visser, Yolande A L Pijnenburg, et al.
Neurology|September 20, 2013
Preclinical AD predicts decline in memory and executive functions in subjective complaintsArgonde C van Harten, Lieke L Smits, Charlotte E Teunissen, et al.
Annals of Clinical and Translational Neurology|September 26, 2018
Pre-amyloid stage of Alzheimer's disease in cognitively normal individualsBetty M Tijms, Lisa Vermunt, Marissa D Zwan, et al.
Brain : a Journal of Neurology|July 18, 2025
CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levelsEleonora M Vromen, Diederick M de Leeuw, Argonde C van Harten, et al.
Neuroimage. Clinical|April 23, 2025
Individualized lesion-symptom mapping using explainable artificial intelligence for the cognitive impact of white matter hyperintensitiesRyanne Offenberg, Alberto De Luca, Geert Jan Biessels, et al.
Journal of Alzheimer'S Disease : JAD|December 31, 2016
Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented ElderlyRosalinde E R Slot, Argonde C Van Harten, Maartje I Kester, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's DiseaseArgonde C van Harten, Joyce Mulders, Philip Scheltens, et al.
Neurobiology of Aging|June 3, 2017
CSF ApoE predicts clinical progression in nondemented APOEε4 carriersArgonde C van Harten, Wesley Jongbloed, Charlotte E Teunissen, et al.
Stroke|July 16, 2015
White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive DeclineMarije R Benedictus, Argonde C van Harten, Annebet E Leeuwis, et al.
Clinical Chemistry and Laboratory Medicine|February 24, 2011
Tau and p-tau as CSF biomarkers in dementia: a meta-analysisArgonde C van Harten, Maartje I Kester, Pieter-Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 13, 2012
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaintsArgonde C van Harten, Pieter Jelle Visser, Yolande A L Pijnenburg, et al.
Neurology|September 20, 2013
Preclinical AD predicts decline in memory and executive functions in subjective complaintsArgonde C van Harten, Lieke L Smits, Charlotte E Teunissen, et al.
Annals of Clinical and Translational Neurology|September 26, 2018
Pre-amyloid stage of Alzheimer's disease in cognitively normal individualsBetty M Tijms, Lisa Vermunt, Marissa D Zwan, et al.
Brain : a Journal of Neurology|July 18, 2025
CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levelsEleonora M Vromen, Diederick M de Leeuw, Argonde C van Harten, et al.
Neuroimage. Clinical|April 23, 2025
Individualized lesion-symptom mapping using explainable artificial intelligence for the cognitive impact of white matter hyperintensitiesRyanne Offenberg, Alberto De Luca, Geert Jan Biessels, et al.
Journal of Alzheimer'S Disease : JAD|December 31, 2016
Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented ElderlyRosalinde E R Slot, Argonde C Van Harten, Maartje I Kester, et al.
Pageof 8